GNL3

Across TCGA pan-cancer cohorts, GNL3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GNL3 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher GNL3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GNL3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CHOL, UCEC, and PCPG are the cancer types where GNL3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Median	All	0.024	0.728	<.001	36	view →
UCEC	DFS	Median	All	1.000	0.626	.011	16	view →
PCPG	OS	Median	All	0.010	0.946	<.001	12	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	12	view →
OV	OS	Median	All	0.277	0.690	.013	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GNL3–CHOL (OS)

Open the CHOL breakdown →